Overview

SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors

Status:
Recruiting
Trial end date:
2024-06-21
Target enrollment:
Participant gender:
Summary
To evaluate the safety and tolerability of SPH5030 tablets in subjects with HER2-positive advanced solid tumors
Phase:
Early Phase 1
Details
Lead Sponsor:
Shanghai Pharmaceuticals Holding Co., Ltd